7 children given bluebird's Skysona developed blood cancer
Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a ...
Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...
The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns ...
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
Another restructuring is underway at bluebird bio Inc., this time with plans to lay off about 25% of the Somerville company’s ...
(BLUE) plans to reduce workforce by 25%, optimize cost structure, focus on commercial launches, and aim for cash flow ...
About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it ...
As part of the restructuring, Bluebird plans to focus further on the ongoing commercial launches of LYFGENIA, ZYNTEGLO, and SKYSONA to enable continued launch acceleration while the company ...
Bluebird bio is shedding about a quarter of its workforce as part of a restructuring plan aimed at reducing its cash operating expenses by around 20% and enabling quarterly cash flow break-even in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback